Genetics of alcoholic liver disease and nonalcoholic fatty liver disease

Seminars in Liver Disease

Volumn 27, Issue 1, 2007, Pages 44-54

  De Alwis, Nimantha Mark Wilfred ^a   Day, Christopher Paul ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Alcoholic liver disease; Nonalcoholic liver disease; Polymorphisms

Indexed keywords

ANGIOTENSINOGEN; CD14 ANTIGEN; CYTOKINE; MANGANESE SUPEROXIDE DISMUTASE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; SATURATED FATTY ACID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; BACTERIAL OVERGROWTH; DNA MICROARRAY; ENVIRONMENTAL FACTOR; FAT INTAKE; FATTY LIVER; GENETIC POLYMORPHISM; GENETIC RISK; GENETICS; HEREDITY; HUMAN; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SLEEP APNEA SYNDROME;

CARCINOMA, HEPATOCELLULAR; CYTOKINES; DISEASE SUSCEPTIBILITY; ENDOTOXINS; ENVIRONMENT; FATTY LIVER; HUMANS; LIFE STYLE; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; MICROARRAY ANALYSIS; OXIDATIVE STRESS; PROTEOMICS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 33847008303     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-960170     Document Type: Review

References (96)

1. Neuschwander-Tetri BA, Caldwell SH. Non alcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37:1202-1219
2. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997;41:845-850
3. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-1110
4. Dixon JB, Bhathal PS, O'Brian PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100
5. Stewart S, Jones D, Day CP. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 2001;7:408-413
6. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:663-678
7. Day CP. From fat to inflammation. Gastroenterology 2006;130:207-210
8. Stewart SF, Vidali M, Day CP, et al. Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. Hepatology 2004;39:197-203
9. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54
10. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver disease in mice. J Clin Invest 2003;112:91-100
11. Grove J, Daly A, Brown A, et al. The Rsa polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics 1998;8:335-342
12. Becker U, Gronbaek M, Johansen D, Sorensen TI. Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology 2002;35:868-875
13. Johansen D, Friis K, Skovenborg E, Gronbaek M. Food buying habits of people who buy wine or beer: cross sectional study. BMJ 2006;332:519-522
14. Rotily M, Durbec J, Berthezene P, Sarles H. Diet and alcohol in liver cirrhosis: a case-control study. Eur J Clin Nutr 1990;44:595-603
15. Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006;166:1190-1195
16. Raynard B, Balian A, Fallick D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002;35:635-638
17. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909-916
18. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206-211
19. Tanne F, Gagnadoux F, Chazouilleres O, et al. Chronic liver injury during obstructive sleep apnea. Hepatology 2005;41:1290-1296
20. Hrubec Z, Omenn G. Evidence for genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans. Alcohol Clin Exp Res 1981;5:207-215
21. Stinson FS, Grant BF, Dufour MC. The critical dimension of ethnicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res 2001;25:1181-1187
22. Caetano R, Clark CL. Trends among alcohol related problems among whites, blacks, and Hispanics: 1984-1995. Alcohol Clin Exp Res 1998;22:534-538
23. Struben VMD, Hespenheide EE, Caldwell SH. Non-alcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000;108:9-13
24. Willner IR, Waters B, Patil SR, et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-2961
25. Browning JD, Kumar JS, Saboorian MH, Theile DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004;99:292-298
26. Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. Is NASH underdiagnosed among African Americans? Am J Gastroenterol 2002;97:1496-1500
27. Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol 2001;52:489-499
28. Rangnekar AS, Lammert F, Igolnikov A, Green RM. Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis. Liver Int 2006;26:1000-1005
29. Deaciuc IV, Arteel GE, Peng X, et al. Gene expression in the liver of rats fed alcohol by means of intragastric infusion. Alcohol 2004;33:17-30
30. Baranova A, Schlauch K, Gowder S, et al. Microarray technology in the study of obesity and non alcoholic fatty liver disease. Liver Int 2005;25:1091-1096
31. Shackel NA, McGuiness PH, Abbot CA, et al. Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis. Gut 2001;49:565-576
32. Shackel NA, McGuiness PH, Abbot CA, et al. Insights into the pathobiology of Hepatitis C virus associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol 2002;160:641-654
33. Seth D, Gorrell MD, Cordoba S, et al. Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol 2006;45:306-320
34. Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003;38:244-251
35. Younossi ZM, Gorreta F, Ong JP, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int 2005;25:760-771
36. Issaq HJ, Conrads TP, Prieto DA, et al. SELDI-TOF MS for diagnostic proteomics. Anal Chem 2003;75:148A-155A
37. Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005;42:665-674
38. Day CP, Bassendine MF. Genetic predisposition to alcoholic liver disease. Gut 1992;33:1444-1447
39. Enomoto N, Yamashina S, Schemmer P, et al. Estriol sensitizes rat Kupffer cells via gut-derived endotoxin. Am J Physiol 1999;277:G671-G677
40. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438
41. Clark JM, Bracanti FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657
42. Ostberg JE, Thomas EL, Hamilton G, et al. Excess visceral and hepatic adipose tissue in Turner syndrome determined by magnetic resonance imaging: estrogen deficiency associated with hepatic adipose content. J Clin Endocrinol Metab 2005;90:2631-2635
43. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005;330:932
44. Shimizu I. Impact of oestrogens on the progression of liver disease. Liver Int 2003;23:63-69
45. Ameen C, Oscarsson J. Sex difference in hepatic microsomal triglyceride transfer protein expression is determined by the growth hormone secretory pattern in the rat. Endocrinology 2003;144:3914-3921
46. Lonardo A, Carani C, Carulli N, Loria P. "Endocrine NAFLD" a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol 2006;44:1196-1207
47. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998;27:1463-1466
48. Namikawa C, Shu-Ping Z, Vyselaar J, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in nonalcoholic steatohepatitis. J Hepatol 2004;40:781-786
49. Bernard S, Touzet S, Personne I, et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000;43:995-999
50. Day CP, Leathart JB, Daly A. Genetic evidence that fatty liver is involved in the pathogenesis of advanced alcoholic liver disease. Hepatology 2002;36(suppl 1):16
51. Song J, da Costa KA, Fischer LM, et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J 2005;19:1266-1271
52. Zintzaras E, Stefanidis I, Santos M, Vidal F. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology 2006;43:352-361
53. Grove J, Daly A, Burt A, et al. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut 1998;43:262-266
54. Savolainen VT, Pajarinen J, Perola M. Glutathione S-Transferase GSTM "null" genotype and the risk of alcoholic liver disease. Alcohol Clin Exp Res 1996;20:1340-1345
55. Ladero JM, Martinez C, Garcia-Martin E, et al. Polymorphisms of the glutathione S-transferase mi-1 (GSTM1) and theta 1 (GSTT1) and the risk of advanced alcoholic liver disease. Scand J Gastroenterol 2005;40:348-353
56. Adachi M, Ishii H. Role of mitochondria in alcoholic liver disease. Free Radic Biol Med 2002;32:487-491
57. Sutton A, Imbert A, Igoudjil A, et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 2005;15:311-319
58. Sutton A, Khoury H, Prip-Buus C, et al. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 2003;13:145-157
59. Degoul F, Sutton A, Mansouri A, et al. Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology 2001;120:1468-1474
60. Stewart SF, Leathart JB, Chen Y, et al. The valine-alanine manganese superoxide dismutase polymorphism is not associated with increased oxidative stress or susceptibility to advanced alcoholic liver disease. Hepatology 2002;36:1355-1360
61. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192
62. Miele L, Grieco A, Armuzzi A, et al. Nonalcoholic steatohepatitis (NASH) and hepatic mitochondrial beta oxidation: hepatic mitochondrial betaoxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. Am J Gastroenterol 2003;98:2335-2365
63. Fan CY, Pan J, Usuda N, et al. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase: implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 1998;273:15639-15645
64. Merriman R, Aouizerat B, Molloy M, et al. A genetic mutation in the peroxisome proliferator-activated receptor alpha gene in patients with non-alcoholic steatohepatitis. Hepatology 2001;34:441A
65. Berger J, Moller D. The mechanism of action of PPARs. Annu Rev Med 2002;53:409-435
66. Sapone A, Peters J, Sakai S, et al. The human peroxisome proliferator-activated receptor gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 2000;10:321-323
67. Ip E, Farrell G, Robertson G, et al. Central role of PPAR-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003;38:123-132
68. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295
69. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-318
70. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004;39:179-187
71. Saksena S, Daly A, Leathart J, Day C. Manganese dependent superoxide dismutase (SOD2) targeting sequence polymorphism is associated with advanced fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2003;38(suppl 2):47
72. Baldini M, Lohman I, Halonen M, et al. A polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999;20:976-983
73. Järveläinen HA, Orpana A, Perola M, et al. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 2001;33:1148-1153
74. Leathart J, Day C, Daly A. No association between functional SNPs in the endotoxin receptors CD14 and TLR4 and alcoholic liver disease (ALD): is endotoxin important in the pathogenesis of ALD in humans? Hepatology 2001;34:459A
75. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187-191
76. Day C. CD14 promoter polymorphism associated with risk of NASH. J Hepatol 2002;36(suppl 1):21
77. Grove J, Daly A, Bassendine M, Day C. Association of a tumor necrosis factor polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997;26:143-146
78. Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumour necrosis factor promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002;122:274-280
79. Pastor IJ, Laso FJ, Romero A, Gonzalez-Sarmiento R. -238 G/A polymorphism of tumour necrosis factor alpha gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men. Alcohol Clin Exp Res 2005;29:1928-1931
80. Grove J, Daly A, Bassendine M, et al. Polymorphism associated with low interleukin-10 production is a risk factor for associated alcoholic liver disease. Gut 2000;46:540-545
81. Takamatsu M, Yamauchi M, Maezawa Y, et al. Genetic polymorphisms of interleukin 1beta in association with the development of alcoholic liver disease in Japanese patients. Am J Gastroenterol 2000;95:1305-1311
82. Vidali M, Stewart S, Rolla R, et al. Genetic and epigenetic factors in auto-immune reactions towards cytochrome P4502E1 in alcoholic liver disease. Hepatology 2003;37:410-419
83. Waterhouse P, Marengere LE, Mittrucker HW, Mak TW. CTLA-4, a negative regulator of T-lymphocyte activation. Immunol Rev 1996;153:183-207
84. Ueda H, Howson J, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506-511
85. Valenti L, De Feo T, Fracanzani AL, et al. Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients. Alcohol Alcohol 2004;39:276-280
86. Bataller R, North K, Brenner D. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003;37:493-503
87. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000;31:828-832
88. Osterreicher CH, Datz C, Stickel F, et al. TGFbeta1 gene polymorphism (codon 25 Arg(Pro) affects progression to cirrhosis in patients with hereditary haemochromatosis). Cytokine 2005;31:142-148
89. Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006;130:1679-1687
90. Bathgate AJ, Pravika V, Perry C. Polymorphisms in tumour necrosis factor alpha, interleukin 10 and transforming growth factor beta 1 genes and end stage liver disease. Eur J Gastroenterol Hepatol 2000;12:1329-1333
91. Oliver J, Agundez JA, Morales S, et al. Polymorphisms in the transforming growth factor beta gene and the risk of advanced alcoholic liver disease. Liver Int 2005;25:935-939
92. Dixon JB, Bhathal PS, Jonsson JR, et al. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 2003;39:967-970
93. Sutton A, Nahon P, Pessayre D, et al. Genetic polymorphisms in antioxidant enzymes modulate hepatic iron accumulation and hepatocellular carcinoma development in patients with alcohol induced cirrhosis. Cancer Res 2006;66:2844-2852
94. Saffroy R, Pham P, Chiappini F, et al. The MTHFR 677C> T polymorphism is associated with an increased risk of hepatocellular carcinoma in patients with alcoholic cirrhosis. Carcinogenesis 2004;25:1443-1448
95. Hillebrandt S, Wasmuth HE, Weiskirchen R, et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 2005;37:835-843
96. Brown SD, Hardisty RE. Mutagenesis strategies for identifying novel loci associated with disease phenotypes. Semin Cell Dev Biol 2003;14:19-24